Literature DB >> 10219780

Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy.

P D Griffiths1, B R Dobson, G R Jones, D T Clarke.   

Abstract

Iron is found in high concentration in some areas of the brain, and increased iron in the substantia nigra is a feature of Parkinson's disease. The purpose of this study was to investigate the physical environment of brain iron in post-mortem tissue to provide information on the possible role of iron in neurodegeneration in Parkinson's disease. Iron has also been implicated as the cause of signal loss in areas of high brain iron on T2-weighted MRI sequences. Knowledge of the physical environment of the brain iron is essential in interpreting the cause of signal change. Post-mortem tissue was obtained from six cases of Parkinson's disease and from six age-matched controls. Iron levels were measured using absorption spectrophotometry. Extended X-ray absorption fine structure was used to evaluate the atomic environment of iron within the substantia nigra and both segments of the globus pallidus. Cryo-electron transmission microscopy was used to probe the iron storage proteins in these areas. Iron levels were increased in the parkinsonian nigra and lateral portion of the globus pallidus. Spectra from the extended X-ray absorption fine structure experiments showed that ferritin was the only storage protein detectable in both control and parkinsonian tissue in all areas studied. Cryo-electron transmission microscopy studies showed that ferritin was more heavily loaded with iron in Parkinson's disease when compared with age-matched controls. In summary we have shown that iron levels are increased in two areas of the brain in Parkinson's disease including the substantia nigra, the site of maximal neurodegeneration. This produces increased loading of ferritin, which is the normal brain iron storage protein. It is possible that increased loading of ferritin may increase the risk of free radical-induced damage. Differences in ferritin loading may explain regional differences in iron's effect on the T2 signal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219780     DOI: 10.1093/brain/122.4.667

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  53 in total

1.  Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine.

Authors:  R Pedrosa; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Optimal MRI methods for direct stereotactic targeting of the subthalamic nucleus and globus pallidus.

Authors:  Ruth L O'Gorman; Karin Shmueli; Keyoumars Ashkan; Michael Samuel; David J Lythgoe; Asal Shahidiani; Stephen J Wastling; Michelle Footman; Richard P Selway; Jozef Jarosz
Journal:  Eur Radiol       Date:  2010-07-21       Impact factor: 5.315

3.  Accumulation of non-transferrin-bound iron by neurons, astrocytes, and microglia.

Authors:  Glenda M Bishop; Theresa N Dang; Ralf Dringen; Stephen R Robinson
Journal:  Neurotox Res       Date:  2010-04-30       Impact factor: 3.911

4.  Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration.

Authors:  Jun Peng; May Lin Oo; Julie K Andersen
Journal:  J Neurochem       Date:  2010-11-04       Impact factor: 5.372

5.  Electron tomography of degenerating neurons in mice with abnormal regulation of iron metabolism.

Authors:  Peijun Zhang; William Land; Stanton Lee; Jemma Juliani; Jonathan Lefman; Sophia R Smith; David Germain; Martin Kessel; Richard Leapman; Tracey A Rouault; Sriram Subramaniam
Journal:  J Struct Biol       Date:  2005-05       Impact factor: 2.867

6.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

7.  Human brain myelination and amyloid beta deposition in Alzheimer's disease.

Authors:  George Bartzokis; Po H Lu; Jim Mintz
Journal:  Alzheimers Dement       Date:  2007-04       Impact factor: 21.566

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.